Might dolutegravir be part of a functional cure for HIV?

Canadian Journal of Microbiology

Volumn 62, Issue 5, 2016, Pages 375-382

  Wainberg, Mark A ^a,b,c   Han, Ying Shan ^a   Mesplède, Thibault ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cure; Dolutegravir; Drug resistance; HIV

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; RALTEGRAVIR; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

DRUG; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; INHIBITOR; MUTATION;

DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; MUTATION; PRIORITY JOURNAL; REVIEW; ANTIVIRAL RESISTANCE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS;

EID: 84964969360     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/cjm-2015-0725     Document Type: Review

References (59)

1. Abdel-Mohsen, M., Wang, C., Strain, M.C., Lada, S.M., Deng, X., Cockerham, L.R., et al. 2015. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS, 29(4): 411-420. doi:10.1097/qad.0000000000000572.
2. Allers, K., and Schneider, T. 2015. CCR5D32 mutation and HIV infection: basis for curative HIV therapy. Curr. Opin.Virol. 14: 24-29. doi:10.1016/j.coviro.2015.06.007.
3. Allers, K., Hutter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., and Schneider, T. 2011. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood, 117(10): 2791-2799. doi:10.1182/blood-2010-09-309591.
4. Ananworanich, J., Schuetz, A., Vandergeeten, C., Sereti, I., de Souza, M., Rerknimitr, R., et al. 2012. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE, 7(3): e33948. doi:10.1371/journal.pone.0033948.
5. Ananworanich, J., Dubé, K., and Chomont, N. 2015. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr. Opin. HIV AIDS, 10(1): 18-28. doi:10.1097/coh.0000000000000122.
6. Anstett, K., Fusco, R., Cutillas, V., Mesplède, T., and Wainberg, M.A. 2015. Dolutegravir-selected HIV-1 containing the N155H and R263K resistance substitutions does not acquire additional compensatory mutations under drug pressure that lead to higher-level resistance and increased replicative capacity. J. Virol. 89(20): 10482-10488. doi:10.1128/jvi.01725-15.
7. Archin, N.M., Vaidya, N.K., Kuruc, J.D., Liberty, A.L., Wiegand, A., Kearney, M.F., et al. 2012. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. USA, 109(24): 9523-9528. doi:10.1073/pnas.1120248109. PMID:22645358.
8. Autran, B. 2015. Robust HIV-specific T cells in post-treatment controllers from the VISCONTI cohort. 8th IAS Conf. on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2015, Vancouver, B.C., Canada. TUPEA093.
9. Barouch, D.H., and Deeks, S.G. 2014. Immunologic strategies for HIV-1 remission and eradication. Science, 345(6193): 169-174. doi:10.1126/science.1255512.
10. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., et al. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature, 503(7475): 224-228. doi:10.1038/nature12744. PMID:24172905.
11. Bruner, K.M., Hosmane, N.N., and Siliciano, R.F. 2015. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 23(4): 192-203. doi:10.1016/j.tim.2015.01.013.
12. Buzon, M.J., Martin-Gayo, E., Pereyra, F., Ouyang, Z., Sun, H., Li, J.Z., et al. 2014. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88(17): 10056-10065. doi:10.1128/jvi.01046-14.
13. Cahn, P., Pozniak, A.L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J.F., et al. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet, 382(9893): 700-708. doi:10.1016/s0140-6736(13)61221-0.
14. Conway, J.M., and Perelson, A.S. 2015. Post-treatment control of HIV infection. Proc. Natl. Acad. Sci. USA, 112(17): 5467-5472. doi:10.1073/pnas.1419162112.
15. Cruciani, M., and Malena, M. 2015. Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Preference and Adherence, 9: 299-310. doi:10.2147/ppa.s65199.
16. DaFonseca, S., Niessl, J., Pouvreau, S., Wacleche, V.S., Gosselin, A., Cleret-Buhot, A., et al. 2015. Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology, 12: 38. doi:10.1186/s12977-015-0164-6.
17. Dey, B., and Berger, E.A. 2015. Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Curr. Opin. HIV AIDS, 10(3): 207-213. doi:10.1097/coh.0000000000000151.
18. Geretti, A.M., Armenia, D., and Ceccherini-Silberstein, F. 2012. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr. Opin. Infect. Dis. 25(6): 677-686. doi:10.1097/QCO.0b013e32835a1de7.
19. Hare, S., Smith, S.J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S.H., and Cherepanov, P. 2011. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharm. 80(4): 565-572. doi:10.1124/mol.111.073189.
20. Hightower, K.E., Wang, R., DeAnda, F., Johns, B.A., Weaver, K., Shen, Y., et al. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55(10): 4552-4559. doi:10.1128/aac.00157-11.
21. Hladik, F. 2015. A new hypothesis on HIV cure. F1000Research, 4: 77. doi:10.12688/f1000research.4529.1.
22. Hocqueloux, L., Avettand-Fenoel, V., Jacquot, S., Prazuck, T., Legac, E., Melard, A., et al. 2013. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J. Antimicrob. Chemother. 68(5): 1169-1178. doi:10.1093/jac/dks533.
23. Hutter, G., Nowak, D., Mossner, M., Ganepola, S., Mussig, A., Allers, K., et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360(7): 692-698. doi:10.1056/NEJMoa0802905.
24. Iyidogan, P., and Anderson, K.S. 2014. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses, 6(10): 4095-4139. doi:10.3390/v6104095.
25. Jain, V., Hartogensis, W., Bacchetti, P., Hunt, P.W., Hatano, H., Sinclair, E., et al. 2013. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J. Infect. Dis. 208(8): 1202-1211. doi:10.1093/infdis/jit311.
26. Jiang, G., Mendes, E.A., Kaiser, P., Wong, D.P., Tang, Y., Cai, I., et al. 2015. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog. 11(7): e1005066. doi:10.1371/journal.ppat.1005066.
27. Katlama, C., Deeks, S.G., Autran, B., Martinez-Picado, J., van Lunzen, J., Rouzioux, C., et al. 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet, 381(9883): 2109-2117. doi:10.1016/s0140-6736(13)60104-x.
28. Khalili, K., Kaminski, R., Gordon, J., Cosentino, L., and Hu, W. 2015. Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J. Neurovirol. 21(3): 310-321. doi:10.1007/s13365-014-0308-9.
29. Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K.W., Ferris, R., et al. 2011. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55(2): 813-821. doi:10.1128/aac.01209-10.
30. Li, J.Z., and Gandhi, R.T. 2014. The sooner, the better: more evidence that early antiretroviral therapy lowers viral reservoirs in HIV-infected infants. J. Infect. Dis. 210(10): 1519-1522. doi:10.1093/infdis/jiu298.
31. Liang, J., Mesplède, T., Oliveira, M., Anstett, K., and Wainberg, M.A. 2015. The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high-level viral replication and the development of high-level drug resistance. J. Virol. 89: 11269-11274. doi:10.1128/jvi.01881-15.
32. Llibre, J.M., Pulido, F., Garcia, F., Garcia Deltoro, M., Blanco, J.L., and Delgado, R. 2015. Genetic barrier to resistance for dolutegravir. AIDS Rev. 17(1): 56-64. PMID:25472016.
33. Luzuriaga, K., Tabak, B., Garber, M., Chen, Y.H., Ziemniak, C., McManus, M.M., et al. 2014. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J. Infect. Dis. 210(10): 1529-1538. doi:10.1093/infdis/jiu297.
34. Martin, A.R., and Siliciano, R.F. 2015. Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure. Annu. Rev. Med. 67: 215-228. doi:10.1146/annurev-med-011514-023043.
35. Mesplède, T., and Wainberg, M.A. 2014. Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses, 6(9): 3377-3385. doi:10.3390/v6093377.
36. Mesplède, T., and Wainberg, M.A. 2015. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses, 7(7): 3703-3718. doi:10.3390/v7072790.
37. Mesplède, T., Quashie, P.K., Osman, N., Han, Y., Singhroy, D.N., Lie, Y., et al. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology, 10:22. doi:10.1186/1742-4690-10-22.
38. Mesplède, T., Moisi, D., Oliveira, M., Ibanescu, I., Ohnona, F., Brenner, B., and Wainberg, M.A. 2015. Dolutegravir inhibits HIV-1 Env evolution in primary human cells. AIDS, 29(6): 659-665. doi:10.1097/qad.0000000000000606.
39. Mousseau, G., Kessing, C.F., Fromentin, R., Trautmann, L., Chomont, N., and Valente, S.T. 2015. The Tat inhibitor didehydro-cortistatin A prevents HIV-1 reactivation from latency. mBio, 6(4): e00465-15. doi:10.1128/mBio.00465-15.
40. Mylvaganam, G.H., Silvestri, G., and Amara, R.R. 2015. HIV therapeutic vaccines: moving towards a functional cure. Curr. Opin. Immunol. 35: 1-8. doi:10.1016/j.coi.2015.05.001.
41. Osman, N., Mesplède, T., Quashie, P.K., Oliveira, M., Zanichelli, V., and Wainberg, M.A. 2015. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J. Antimicrob. Chemother. 70(10): 2810-2815. doi:10.1093/jac/dkv176.
42. Pace, M., and Frater, J. 2014. A cure for HIV: Is it in sight? Expert Rev. Anti-Infect. Ther. 12(7): 783-791. doi:10.1586/14787210.2014.910112.
43. Purcell, D.F., Elliott, J.H., Ross, A.L., and Frater, J. 2013. Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium. Retrovirology, 10: 134. doi:10.1186/1742-4690-10-134.
44. Quashie, P.K., Mesplède, T., Han, Y.S., Oliveira, M., Singhroy, D.N., Fujiwara, T., et al. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J. Virol. 86(5): 2696-2705. doi:10.1128/jvi.06591-11.
45. Quashie, P.K., Mesplède, T., Han, Y.S., Veres, T., Osman, N., Hassounah, S., et al. 2013a. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob. Agents Chemother. 57(12): 6223-6235. doi:10.1128/aac.01835-13.
46. Quashie, P.K., Mesplède, T., and Wainberg, M.A. 2013b. Evolution of HIV integrase resistance mutations. Curr. Opin. Infect. Dis. 26(1): 43-49. doi:10.1097/QCO.0b013e32835ba81c.
47. Quashie, P.K., Oliviera, M., Veres, T., Osman, N., Han, Y.S., Hassounah, S., et al. 2015. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J. Virol. 89(6): 3163-3175. doi:10.1128/jvi.03353-14.
48. Saez-Cirión, A. 2015. HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected child. 8th IAS Conf. on HIV Pathogenesis, Treatment and Prevention 19-22 July 2015, Vancouver: MOAA0105LB.
49. Saez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., et al. 2013. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9(3): e1003211. doi:10.1371/journal.ppat.1003211.
50. Seki, T., Suyama-Kagitani, A., Kawauchi-Miki, S., Miki, S., Wakasa-Morimoto, C., Akihisa, E., et al. 2015. Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob. Agents Chemother. 59(5): 2596-2606. doi:10.1128/aac.04844-14.
51. Siliciano, J.D., and Siliciano, R.F. 2014. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J. Allergy Clin. Immunol. 134(1): 12-19. doi:10.1016/j.jaci.2014.05.026.
52. Simonetti, F.R., and Kearney, M.F. 2015. Review: Influence of ART on HIV genetics. Curr. Opin. HIV AIDS, 10(1): 49-54. doi:10.1097/coh.0000000000000120.
53. Solomon, D.A., and Sax, P.E. 2015. Current state and limitations of daily oral therapy for treatment. Curr. Opin. HIV AIDS, 10(4): 219-225. doi:10.1097/coh.0000000000000165.
54. Thornhill, J., Fidler, S., and Frater, J. 2015. Advancing the HIV cure agenda: the next 5 years. Curr. Opin. Infect. Dis. 28(1): 1-9. doi:10.1097/qco.0000000000000123.
55. Wainberg, M.A., and Han, Y.S. 2015. Will drug resistance against dolutegravir in initial therapy ever occur? Front. Pharmacol. 6: 90. doi:10.3389/fphar.2015.00090.
56. Wainberg, M., Anstett, K., Mesplède, T., Quashie, P., Han, Y., and Oliveira, M. 2014. The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. J. Int. AIDS Soc. 17(4 Suppl 3): 19518. doi:10.7448/ias.17.4.19518.
57. Wares, M., Mesplède, T., Quashie, P.K., Osman, N., Han, Y., and Wainberg, M.A. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology, 11: 7. doi:10.1186/1742-4690-11-7.
58. White, K.L., Raffi, F., and Miller, M.D. 2014. Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients. Viruses, 6(7): 2858-2879. doi:10.3390/v6072858.
59. Whitney, J.B., Hill, A.L., Sanisetty, S., Penaloza-MacMaster, P., Liu, J., Shetty, et al. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature, 512(7512): 74-77. doi:10.1038/nature13594.